The experimental drug neflamapimod reduced a key biomarker of neurodegeneration, which correlated with a slowing of cognitive ...

New data from a phase IIb trial extension study suggested that investigational neflamapimod led to significant improvements ...

Treatment with neflamapimod slowed clinical worsening and led to reduced disease-related plasma biomarkers in individuals with dementia with Lewy bodies, according to a speaker at CTAD. “Dementia with ...

As it turns out, you learn a lot more from competing in the Rebelle Rally than just navigating and off-road […] ...

Significant reduction in key neurodegeneration biomarker correlated with treatment response, suggesting neflamapimod may act on underlying disease CervoMed preparing to initiate Phase 3 registrational ...

People with multimorbidity, defined as two or more long‐term conditions occurring within the same patient at the same time, ...

Trump gets a lot of things wrong when he talks about cognitive tests. He recently bragged to journalists that he “aced” one, and said the doctors at Walter Reed told him no president had taken a ...

Around one million people in the UK live with dementia, yet Alzheimer's Society says one in three don't have a diagnosis.

NEW YORK (AP) — The former CEO of Abercrombie & Fitch faces a March court hearing to determine whether he’s competent to ...

What’s more, the incidence of early onset dementia, before the age of 60 or 65 years, is also emerging as a significant ...

British scientists believe they have found a groundbreaking way to test for dementia via the nose decades before symptoms ...

Just recently, I found out that one of my closest friends had been diagnosed with early-stage dementia and it hit me hard. He’s someone ...